Vanderbilt-Ingram Cancer Center

None Provided.

Criteria
 DISEASE CHARACTERISTICS:

 • Diagnosis of primary cancer at age 21 or younger

 • In active follow-up by a Children's Oncology Group (COG) institution

 • Date of last visit or contact by a COG institution within the past 24 months

 • Case group

 • Development of one of the following key adverse events after initiation of prior cancer therapy:

 • Cardiac dysfunction, meeting 1 of the following criteria (closed to accrual as of 4/17/09):

 • Symptomatic cardiac dysfunction, including current or previous diagnosis of congestive heart failure based on any of the following clinical criteria:

 • Pulmonary and/or peripheral edema

 • Dyspnea

 • Orthopnea

 • Fatigue

 • Hepatomegaly

 • Asymptomatic cardiac dysfunction

 • Ejection fraction < 40% on echocardiogram OR MUGA and/or fractional shortening < 28% on echocardiogram without clinical symptoms

 • Myocardial infarction, meeting 1 of the following criteria (closed to accrual as of 6/5/06):

 • Definite ECG changes

 • Typical, atypical, or inadequately described symptoms AND probable ECG, AND abnormal enzymes, including creatine kinase MB

 • Typical symptoms AND abnormal enzymes, including creatine kinase MB, AND ischemic ECG, non-codable ECG, or ECG not available

 • Ischemic stroke, meeting the following criteria:

 • Fixed neurological deficit lasting more than 24 hours

 • Confirmed by CT scan or MRI within 7 days of onset of symptoms

 • No subarachnoid or intracerebral hemorrhage, transient ischemic attacks, or amaurosis fugax

 • Avascular necrosis, meeting the following criteria (closed to accrual as of 11/26/08):

 • Clinical symptoms of joint pain, joint stiffness, or decreased range of motion

 • Confirmed by plain radiographs, CT scan, MRI, or bone scan

 • Subsequent malignant neoplasm, meeting the following criteria:

 • Histologically distinct neoplasm developing in patients treated for a primary cancer

 • Confirmed by an institutional pathology report

 • Control group

 • No clinical evidence of any of the following:

 • Cardiac dysfunction (closed to accrual as of 4/17/09)

 • Myocardial infarction (closed to accrual as of 6/5/06)

 • Ischemic stroke

 • Avascular necrosis (closed to accrual as of 11/26/08)

 • Subsequent malignant neoplasm

 PATIENT CHARACTERISTICS:

 Age

 • 21 and under at diagnosis, any age at study entry

 Performance status

 • Not specified

 Life expectancy

 • Not specified

 Hematopoietic

 • Not specified

 Hepatic

 • Not specified

 Renal

 • Not specified

 Cardiovascular

 • See Disease Characteristics

 PRIOR CONCURRENT THERAPY:

 Biologic therapy

 • Not specified

 Chemotherapy

 • Not specified

 Endocrine therapy

 • Not specified

 Radiotherapy

 • Not specified

 Surgery

 • Not specified

 Other

 • No prior allogeneic (non-autologous) hematopoietic cell transplant